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Background: The radiation resistance of prostate cancer remains the primary obstacle to improve patient survival.
This study aimed to investigate the effects of berberine, a commonly used natural product, on the radiosensitivity
of prostate cancer.
Methods: Prostate cancer cell line LNCaP and DU-145 were subjected to hypoxia and/or ionizing radiation (IR), in
the presence or absence of berberine treatment. Cell growth and colony formation, and apoptosis were evaluated.
Moreover, LNCaP cells were xenografted into nude mice and subjected to IR and/or berberine treatment. The
expression of HIF-1α and VEGF in prostate cancer cells and xenografts was detected by Western blot analysis.
Results: Berberine increased radiosensitivity of prostate cancer cells and xenografts in a dose dependent manner,
and this was correlated with the inhibition of HIF-1α and VEGF expression.
Conclusions: Berberine may inhibit the expression of HIF-1α and VEGF and thus confer radiosensitivity on prostatic
cancer cells. Berberine has potential application as an adjuvant in radiotherapy of prostatic cancer.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1519827543125021.
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Prostate cancer (PCa) is the most common malignancy
in men and the second leading cause of death from can-
cer. Asian prostate cancer patients had better survival
but the incidence rate of PCa has been increasing rapidly
in recent years [1]. Currently, radiation therapy is the
main treatment for PCa and provides excellent local
control and increased overall survival for PCa patients
[2]. However, some PCa patients exhibit radiation resist-
ance and develop metastatic disease in less than 5 years* Correspondence: mjx3416@126.com
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unless otherwise stated.[3]. Thus it is an important issue to reduce radiation re-
sistance and increase radiosensitivity of PCa.
Hypoxia is a common feature of malignant tumors and
makes solid tumors resistant to ionizing radiation (IR) [4].
Hypoxia inducible factor-1 (HIF-1) is one of the main reg-
ulators of cell response to hypoxia. HIF-1α is a subunit of
HIF-1 and regulates the expression of a variety of down-
stream target genes, including vascular endothelial growth
factor (VEGF), and could confer resistance to radiation
therapy and chemotherapy [5,6].
Berberine is a quaternary ammonium salt from the
protoberberine group of isoquinoline alkaloids. A num-
ber of studies have shown that berberine has anti-tumor
activity for a variety of cancers. However, the effects of
berberine on PCa have not been reported. In this study,
we showed that berberine could inhibit HIF-1α expressionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Moreover, we found that berberine could sensitize nude
mice bearing PCa cells to IR by inhibiting the expression
of HIF-1α and VEGF.
Methods
Cell culture and treatment
Human prostate cancer cell lines LNCaP and DU-145
were purchased from Shanghai Cell Bank, and cultured
in RPMI-1640 medium (Invitrogen) supplemented with
10% fetal bovine serum (Invitrogen), 100 U/ml penicillin
and 100 mg/ml streptomycin at 37°C in 5% CO2 and
21% O2 or 0.8% O2 in a humidified atmosphere. Ex-
ponentially growing cells were detached using 0.05%
trypsin-EDTA every 2–3 days. The cells were irradiated
in ambient air with 6 MV X-rays at a dose rate of
5.66 Gy/min at room temperature. Berberine hydro-
chloride (>95%) was purchased from Sigma Aldrich.
MTT assay
Cells in early log phase were trypsinized and plated in
96-well plates at a density of 4,000 cells/well. After 24 h,
the medium was removed and replaced with fresh me-
dium supplemented with different concentrations of ber-
berine (20, 50, 100, 150, 200, 250, 300, 400 μM). Cell
viability was detected on day 1, 2 and 3 by MTT assay
following the manufacturer’s instructions. Briefly, 10 μl
of MTT was added into each well to a final concent-
ration of 0.5 mg/ml. After incubation for 4 h, the cell
supernatants were removed and DMSO (150 μl) was ad-
ded to dissolve MTT crystals (formazan). The absorb-
ance of the samples at 490 nm was read using a Bio-Rad
microplate reader (model 630; Hercules, CA, USA).
Clonogenic assay
Cells in early log phase were trypsinized and plated in 6-
well plates. Then the cells were treated with or without
bererine for the indicated time and then subjected to
X-rays of 2, 4, 6, 8 Gy at room temperature. The cells
were incubated at 37°C for 12 days for LNCaP cells and
14 days for DU-145 cells, fixed with methanol and
stained with Giemsa. Finally, the plates were inspected
by microscopy and the number of the colonies with at
least 50 cells was counted.
Flow cytometry analysis of apoptosis
Cells in early log phase were trypsinized and plated in
6-well plates at a specific density. The cells were treated
with or without bererine in normxia or hypoxia for 24 h,
then exposed to X-rays (6 Gy). After 3 h, the cells were
collected and incubated with Annexin V and propidium
iodide for 15 min. The apoptotic cells were detected by
flow cytometry using light scatter characteristics (BD
Bioscience, Oxford, UK).Western blot analysis
Total cell lysates were prepared by harvesting cells in
protein extraction buffer, and protein concentration
was analyzed using the BCA protein assay kit. Equal
amounts of proteins were separated on 6% or 10%
SDS-polyacrylamide gel, transferred onto nitrocellulose
membranes (Schleicher and Schuell Bio-Science). The
membranes were blocked with 5% nonfat milk in TBST
(Tris-buffered saline, pH 7.4 and 0.05% Tween 20) and
incubated with HIF-1α antibody (1:200), VEGF an-
tibody (1:250) and β-actin antibody (1:250) (all from
Santa Cruz Biotechnology Inc, CA, USA) overnight at
4°C. The membranes were then incubated with alkaline
phosphatase-conjugated goat anti-mouse IgG or goat
anti-rabbit IgG (1:2000) for 1 h at room temperature,
and the signals were detected by using enhanced che-
miluminescence detection kit.
Immunofuorescence
Cells in early log phase were trypsinized and plated in
24-well plates at a density of 4,000 cells/well. The cells
were exposed to bererine and/or hypoxia for 24 h. Cells
were fixed with methanol at −20°C for 20 min, and
washed 3 times with PBS. Next the cells were incubated
with goat anti-mouse HIF-1α antibody (1:250) or goat
anti-rabbit VEGF antibody (1:250) for 16 h at 4°C, then
incubated with anti-mouse-FITC or anti-rabbit-FITC
(Jackson, USA) at a dilution of 1:150 for 1.5 h in the
dark at room temperature. Finally, cells were mounted
onto glass slides and observed under Confocal Laser
Scanning Microscope (Zeiss LSM510).
Tumor xenograft mouse models
Animal experiments were approved by Ethics Commit-
tee of Nanjing Medical University. Male BALB/C nude
mice (4–5 weeks old) were provided by Nanjing Medical
University Animal Center. Mice were then subcutaneously
inoculated with LNCaP cells (5 × 106 cells in 0.1 ml of
PBS) at one site of the right armpit. When the average vol-
ume of tumour (visualized as small nodules at the sites of
injection) increased to 150 mm3, the animals were ran-
domly grouped into 6 different groups (n = 6): (1) vehicle
(PBS), (2) 5 mg/kg berberine, (3) 10 mg/kg berberine, (4)
8 Gy IR, (5) 5 mg/kg berberine plus 8 Gy IR, (6) 10 mg/kg
berberine plus 8 Gy IR. The mice in control group were
treated with vehicle control, whereas the mice in 2, 3, 5
and 6 groups were given daily intraperitoneal injection of
5 or 10 mg/kg berberine every two days for 6 times.
Tumors were irradiated by RS-2000 biological irradiator
at a dose of 8 Gy with X-rays (2 Gy/min) delivered 2 h
after injection on day 12. Tumor growth was measured
every two days, the tumor volume was calculated accord-
ing to the formula: Tumor volume = [length (L) × width
(W)]2/2. The percentage of tumor growth inhibition (TGI)
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the tumor volume in each group/mean change in the
tumor volume in the control group)] × 100. The tumor
doubling time (DT) was calculated as follows: DT = d ×
lg2/lg(Vd/V0), where d was the length of time between
two measurements, Vd was the volume of the tumor
treated with X-ray and V0 was the volume of the tumor
before the X-ray.
Statistical analysis
Data were expressed as mean ± Standard Deviation (SD)
of at least three independent experiments, and analyzed
by SPSS statistical software system for Windows version
16.0 (SPSS Inc. Chicago, USA). Statistical significance
was determined by using Student’s t-test and p < 0.05
was considered significant.
Results
Berberine sensitizes prostatic cancer cells to IR in
normoxia and hypoxia conditions
The viability of PCa cell lines LNCaP and DU-145 cells
was detected after treatment with different concentrationsFigure 1 Berberine sensitizes LNCaP and DU-145 cells to IR. (A) berbe
dose-dependent manner. (B) berberine inhibited the colony formation of L
berberine for 24 h in hypoxia, and then exposed to X-ray (6 Gy). After 3 h,
rate of apoptosis from three independent experiments in LNCaP and DU-1
(6 Gy), DU-145: p = 0.0056, hypoxia + IR (6 Gy) vs. hypoxia + Ber30 + IR (6 Gyof berberine for 12, 24, 48 and 72 h, respectively. MTT
assay showed that berberine reduced the cell viability in a
concentration and time dependent manner (Figure 1A).
At 24 h, the IC50 of berberine for LNCaP and DU-145
cells were 220.36 μΜ and 163.56 μΜ, respectively.
Thus we chose the concentrations of berberine at 30 and
50 μM for subsequent experiments.
Clonogenic assay showed the radiation dose–response
survival curves for LNCaP and DU-145 cells with or
without berberine treatment for 24 h in normoxia and
hypoxia conditions (Figure 1B). Both normoxic and hyp-
oxic PCa cells that were pretreated with berberine exhibi-
ted a significantly increased sensitivity to IR, as reflected by
the remarkable decrease in their ability to form colonies.
The induction of apoptotic cell death is an important
mechanism by which radio-/chemotherapy kills tumor
cells. Next we detected apoptosis in LNCaP and DU-145
cells treated by berberine or/and IR (6 Gy). The rate of
apoptotic cell death was higher in cells pretreated with
50 μM berberine than in cells pretreated with 30 μM
berberine. Furthermore, berberine (30 μΜ and 50 μΜ)
combined with IR, the rate of apoptotic cell death wasrine inhibited the growth of LNCaP and DU-145 cells in a time- and
NCaP and DU-145 cells. (C) LNCaP and DU-145 cells were treated with
apoptotic cells were detected by flow cytometry. (D) bars showing the
45 cells. LNCaP: p = 0.045, hypoxia + IR (6 Gy) vs. hypoxia + Ber30 + IR
). Ber: berberine, 30: 30 μM, 50: 50 μM.
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IR than in cells treated with IR alone (Figure 1C,D).
Berberine inhibits HIF-1α and VEGF expression in
prostatic cancer cells
To investigate whether HIF-1α and VEGF are involved
in berberine mediated radiosensitivity of prostatic cancer
cells, we performed Western blot and immunofuorescence
analysis to detect the protein expression of HIF-1α and
VEGF. The results showed that hypoxia induced the ex-
pression of HIF-1α and VEGF in LNCaP and DU-145
cells (Figure 2A). Similarly, IR induced the expression of
HIF-1α and VEGF in LNCaP and DU-145 cells (Figure 2B).
However, the expression of HIF-1α and VEGF was de-
creased in hypoxic LNCaP and DU-145 cells treated with
berberine compared to cells treated with hypoxia alone
(Figure 2C). Furthermore, the expression of HIF-1α and
VEGF was decreased in LNCaP and DU-145 cells treated
with the combination of berberine and IR compared to
cells treated with IR alone (Figure 2D). Moreover, the ef-
fects of berberine on HIF-1α and VEGF expression were
concentration dependent (Figure 2C and Figure 2D).
Furthermore, immunofluorescence analysis showed that
HIF-1α was only located in the nucleus of normoxic
cells, but VEGF was distributed in both the nucleusFigure 2 Berberine inhibits the expression of HIF-1α and VEGF in LNC
expression in LNCaP and DU-145 cells. (B) IR stimulated HIF-1α and VEGF e
VEGF was stimulated in hypoxia conditions and inhibited by berberine in L
stimulated after IR and inhibited by berberine in LNCaP and DU-145 cells. βand cytoplasm (Figure 3). The translocation of HIF-1α
and VEGF into the nucleus was observed in hypoxic
LNCaP and DU-145 cells, which was inhibited promin-
ently by berberine. And high concentration of berberine
(50 μM) exhibited stronger inhibitory effects than the low
concentration (30 μM). Taken together, these results sug-
gest that berberine inhibits the expression of HIF-1α and
VEGF in LNCaP and DU-145 cells.
Berberine sensitizes prostatic cancer to IR in vivo
We next evaluated the effects of berberine on the radio-
sensitivity of PCa in vivo.Tumors were induced by s.c. in-
jection of LNCaP cells into nude mice. We measured the
body weight of the nude mice every week and the tumor
volume every four days. The results showed that none of
the treatment regimens produced any loss of body weight,
which may be a sign of toxicity (Figure 4A). Combined
treatment with IR and berberine significantly suppressed
tumor volume and tumor weight in nude mice, compared
to IR or berberine treatment alone (Figure 4B-D). As
shown in Table 1, tumor growth delay (TGD) time for the
28-day treatment of Ber (5 or 10 mg/kg) alone was 12.3 or
13.1 days, not significantly different from that of control
group (p = 0.3453, p = 0.2526, respectively). IR alone pro-
duced a TGD time of 5.7 days (p = 0.0116 compared toaP and DU-145 cells. (A) hypoxia stimulated HIF-1α and VEGF
xpression in LNCaP and DU-145 cells. (C) The expression of HIF-1α and
NCaP and DU-145 cells. (D) The expression of HIF-1α and VEGF was
-actin was loading control. Ber: berberine.
Figure 3 Berberine inhibits the nuclear location of HIF-1α and VEGF in LNCaP and DU-145 cells. Representative images of laser scanning
confocal microscopy showed nuclear colocalization of HIF-1α and VEGF (green stain) in cells with hypoxia with or without berberine treatment
(30 μM and 50 μM). Ber: berberine, 30: 30 μM, 50: 50 μM.
Figure 4 Berberine increases radiosensitivity of LNCaP xenografts. (A) Measurement of body weight in nude mice once per week. (B)
Measurement of tumor volume in nude mice every four days. Data were presented as the relative tumor volume normalized to the initial tumor
volume measured on day 0. (C) Measurement of tumor weight in the nude mice after sacrifice. P < 0.005, IR vs. berberine (5 or 10 mg/kg) + IR,
(D) Visual observation of the tumors in each group. (E) Western blots showing the expression of HIF-1α and VEGF in LNCaP mouse xenograft
tissues. Ber: berberine, 5: 5 mg/kg, 10: 10 mg/kg, IR: 8 Gy.
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Table 1 Effect of berberine on response of ECA109 xenografted tumor to irradiation






Control 5 10.8 ± 1.2
Ber5 5 27.6 ± 6.3 12.3 ± 2.5 1.5(12.3-10.8)
Ber10 5 58.1 ± 8.6 13.1 ± 3.0 2.3(13.1-10.8)
IR 5 37.8 ± 6.9 16.5 ± 1.5 5.7(16.5-10.8)
IR + Ber5 5 66.6 ± 9.2 21.4 ± 0.7 10.6(21.4-10.8) 9.1(10.6-1.5) 1.6(9.1/5.7)
IR + Ber10 5 75.9 ± 5.9 22.7 ± 4.6 11.9(22.7-10.8) 9.6(11.9-2.3) 1.7(9.6/5.7)
*Tumor growth inhibition rate was calculated based on the tumor volume on Day 40.
**Absolute growth delay: The doubling tumor time of treatment group minus that of control group;
***Normalized growth delay: The time of absolute growth delay of tumor in IR combined with Ber group minus that of Ber group.
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berine (5 or 10 mg/kg) resulted in a TGD time of 21.4 or
22.7 days, respectively (p < 0.05, compared with IR alone
or berberine alone). Moreover, the combined treatment
of IR and berberine (5 or 10 mg/kg) resulted in tumor
growth inhibition of 66.6% and 75.9% on Day 40, res-
pectively. Collectively, these data suggest that berberine
sensitizes PCa to IR in vivo.
Berberine inhibits HIF-1α and VEGF expression in
xenografts induced by IR
Finally, we examined the effects of berberine on the ex-
pression of HIF-1α and VEGF in xenografts. Western blot
analysis showed that berberine decreased IR-induced ex-
pression of HIF-1α and VEGF in LNCaP xenografts in a
concentration dependent manner (Figure 4E).
Discussion
It is crucially to predict pathological outcomes prior
to surgery for appropriate surgical indication of PCa
patients who receive radical prostatectomy [7]. Several
biomarkers have been implicated in the initiation and
progression of PCa [8,9]. Currently, the radiation resist-
ance of prostate cancer remains the primary obstacle to
improve patient survival. Several studies have investi-
gated the mechanism underlying the radiosensitivity for
the treatment of PCa. The inactivation of clusterin by
anti-sense technology improved the outcomes of radiation
therapy for prostate cancer patients [10]. Furthermore,
a recent study showed that arsenic trioxide enhanced
the radiation sensitivity of PCa through the inhibition
of Akt/mTOR signaling pathways [11]. Importantly,
HIF-1α is commonly upregulated in hypoxic tumour
tissues, which may render resistance to radiotherapy [12].
Some anti-cancer drugs increase cancer cells radiosensi-
tivity by downregulating HIF-1α [13].
It is well known that natural compounds confer radio-
sensitivity on cancer cells, such as curcumin and berber-
ine [14-16]. However, there has been no report on the
effects of berberine on the radiosensitivity of PCa. In thecurrent study, we demonstrated for the first time that
berberine could efficiently downregulate HIF-1α expres-
sion in hypoxic prostate cancer cells in vitro and in vivo.
Berberine treatment also inhibited the upregulation of
HIF-1α induced by IR in vitro and in vivo. Consistent
with the downregulation of HIF-1α, we observed that ber-
berine decreased colony formation and increased apop-
tosis in hypoxic LNCaP and DU-145 cells. Therefore,
berberine increases the radiosensitivity of prostate cancer
and better therapy efficacy could be achieved for com-
bined treatment of PCa with IR and berberine.Conclusions
In summary, we showed that berberine at low concen-
trations substantially radiosensitized hypoxic prostate
cancer cells by downregulating HIF-1α and VEGF ex-
pression, which may contribute to tumor aggressiveness,
invasiveness and resistance to IR. Our findings suggest
that berberine could be a novel radiosensitizer for PCa
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